Sharp John P Insider Trades

Insider Trading History

Track insider trading activity for Sharp John P. See latest buy and sell transactions across all companies.

Holdings

Company
Holding Value
Last Transaction
Sale/Purchase
Amount
Price
Current Price

Insider Trades History

Company
Holding Value
Last Transaction
Sale/Purchase
Amount
Price
Current Price
PhaseBio Pharmaceuticals
PhaseBio Pharmaceuticals PHAS
Chief Financial Officer
Holding Value $4.61k 65,767 shares
Last Trade
May 20, 2022 Purchase (Award)Shares received as a grant, bonus, or other company award rather than an open-market purchase.
$4.83k 6,026 shares
$0.80
$0.07
PhaseBio Pharmaceuticals
PhaseBio Pharmaceuticals PHAS
Chief Financial Officer
Holding Value $8.1k 115,500 shares
Last Trade
Feb 24, 2022 Purchase (Award)Shares received as a grant, bonus, or other company award rather than an open-market purchase.
$158k 140,250 shares
$1.13
$0.07
PhaseBio Pharmaceuticals
PhaseBio Pharmaceuticals PHAS
Chief Financial Officer
Holding Value $4.19k 59,741 shares
Last Trade
Nov 19, 2021 Purchase (Award)Shares received as a grant, bonus, or other company award rather than an open-market purchase.
$4.76k 2,017 shares
$2.36
$0.07
PhaseBio Pharmaceuticals
PhaseBio Pharmaceuticals PHAS
Chief Financial Officer
Holding Value $6.35k 90,582 shares
Last Trade
Nov 03, 2021 Sale (Option Exercise)Shares acquired or sold by exercising stock options or converting another derivative security.
$28.7k 7,500 shares
$3.82
$0.07
PhaseBio Pharmaceuticals
PhaseBio Pharmaceuticals PHAS
Chief Financial Officer
Holding Value $4.05k 57,724 shares
Last Trade
Nov 03, 2021 Purchase (Option Exercise)Shares acquired or sold by exercising stock options or converting another derivative security.
$28.7k 7,500 shares
$3.82
$0.07
PhaseBio Pharmaceuticals
PhaseBio Pharmaceuticals PHAS
Chief Financial Officer
Holding Value $3.52k 50,224 shares
Last Trade
Aug 03, 2021 Purchase (Option Exercise)Shares acquired or sold by exercising stock options or converting another derivative security.
$26.4k 7,500 shares
$3.52
$0.07
PhaseBio Pharmaceuticals
PhaseBio Pharmaceuticals PHAS
Chief Financial Officer
Holding Value $6.88k 98,082 shares
Last Trade
Aug 03, 2021 Sale (Option Exercise)Shares acquired or sold by exercising stock options or converting another derivative security.
$26.4k 7,500 shares
$3.52
$0.07
PhaseBio Pharmaceuticals
PhaseBio Pharmaceuticals PHAS
Chief Financial Officer
Holding Value $3.52k 50,224 shares
Last Trade
Aug 03, 2021 Purchase (Award)Shares received as a grant, bonus, or other company award rather than an open-market purchase.
$26.4k 7,500 shares
$3.52
$0.07
PhaseBio Pharmaceuticals
PhaseBio Pharmaceuticals PHAS
Chief Financial Officer
Holding Value $2.99k 42,724 shares
Last Trade
May 20, 2021 Purchase (Award)Shares received as a grant, bonus, or other company award rather than an open-market purchase.
$4.67k 1,419 shares
$3.29
$0.07
PhaseBio Pharmaceuticals
PhaseBio Pharmaceuticals PHAS
Chief Financial Officer
Holding Value $5.36k 76,500 shares
Last Trade
Feb 05, 2021 Purchase (Award)Shares received as a grant, bonus, or other company award rather than an open-market purchase.
$330k 76,500 shares
$4.31
$0.07
PhaseBio Pharmaceuticals
PhaseBio Pharmaceuticals PHAS
Chief Financial Officer
Holding Value $2.9k 41,305 shares
Last Trade
Nov 20, 2020 Purchase (Award)Shares received as a grant, bonus, or other company award rather than an open-market purchase.
$4.61k 1,305 shares
$3.53
$0.07
PhaseBio Pharmaceuticals
PhaseBio Pharmaceuticals PHAS
Chief Financial Officer
Holding Value $7.4k 105,582 shares
Last Trade
Aug 14, 2020 Sale (Option Exercise)Shares acquired or sold by exercising stock options or converting another derivative security.
$20.1k 5,000 shares
$4.02
$0.07
PhaseBio Pharmaceuticals
PhaseBio Pharmaceuticals PHAS
Chief Financial Officer
Holding Value $2.8k 40,000 shares
Last Trade
Aug 14, 2020 Purchase (Option Exercise)Shares acquired or sold by exercising stock options or converting another derivative security.
$20.1k 5,000 shares
$4.02
$0.07
PhaseBio Pharmaceuticals
PhaseBio Pharmaceuticals PHAS
Chief Financial Officer
Holding Value $7.01k 100,000 shares
Last Trade
Feb 12, 2020 Purchase (Award)Shares received as a grant, bonus, or other company award rather than an open-market purchase.
$519k 100,000 shares
$5.19
$0.07
PhaseBio Pharmaceuticals
PhaseBio Pharmaceuticals PHAS
CFO And Secretary
Holding Value $2.45k 35,000 shares
Last Trade
Aug 21, 2019 Purchase (Option Exercise)Shares acquired or sold by exercising stock options or converting another derivative security.
$129k 15,000 shares
$8.59
$0.07
PhaseBio Pharmaceuticals
PhaseBio Pharmaceuticals PHAS
CFO And Secretary
Holding Value $7.75k 110,582 shares
Last Trade
Aug 21, 2019 Sale (Option Exercise)Shares acquired or sold by exercising stock options or converting another derivative security.
$129k 15,000 shares
$8.59
$0.07
PhaseBio Pharmaceuticals
PhaseBio Pharmaceuticals PHAS
CFO And Secretary
Holding Value $8.45k 120,582 shares
Last Trade
May 22, 2019 Sale (Option Exercise)Shares acquired or sold by exercising stock options or converting another derivative security.
$159k 15,000 shares
$10.58
$0.07
PhaseBio Pharmaceuticals
PhaseBio Pharmaceuticals PHAS
CFO And Secretary
Holding Value $1.4k 20,000 shares
Last Trade
May 22, 2019 Purchase (Option Exercise)Shares acquired or sold by exercising stock options or converting another derivative security.
$159k 15,000 shares
$10.58
$0.07
PhaseBio Pharmaceuticals
PhaseBio Pharmaceuticals PHAS
CFO And Secretary
Holding Value $7.01k 100,000 shares
Last Trade
Feb 27, 2019 Purchase (Award)Shares received as a grant, bonus, or other company award rather than an open-market purchase.
$315k 100,000 shares
$3.15
$0.07
PhaseBio Pharmaceuticals
PhaseBio Pharmaceuticals PHAS
CFO And Secretary
Holding Value $351 5,000 shares
Last Trade
Dec 07, 2018 Purchase (Open Market)Shares bought on the open market or in a private purchase outside of a company compensation plan.
$19.2k 5,000 shares
$3.84
$0.07

See more insider trades for free

Join Stockcircle to see more insider trades and be the first to know about new executive transactions.

Sign Up